Another strong readout could redefine how Her2-negative breast cancer is treated, though a declared victory in triple-negatives is less clear.
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?
Rubraca has scored in an all-comers, first-line ovarian cancer maintenance setting, but Clovis has bigger problems.
The Lag3 inhibitor is now approved in melanoma, but Bristol looks unlikely to stop there in its search for a safer Yervoy.
A handful of medtechs will benefit from new reimbursement pathways – but others have been denied the chance.